AaronSKesselheimMD

PubMed

• Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
  Ian T T Liu, Edward R Scheffer Cliff, Aaron S Kesselheim> ;JAMA. 2024 Apr 7
• Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
  Sonya Davey, Kevin Costello, Massimiliano Russo, Suzanne Davies, Hussain S Lalani, Aaron S Kesselheim, Benjamin N Rome> ;JAMA Health Forum. 2024 Apr 5
• Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
  Ariadna Tibau, Thomas J Hwang, Consolacion Molto, Jerry Avorn, Aaron S Kesselheim> ;JAMA Oncology. 2024 Apr 4
• Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015-2019.
  Rachel E Barenie, Brian T Bateman, Hilary S Connery, Theodore Tsacogianis, Aaron S Kesselheim> ;Journal of Substance Use and Addiction Treatment. 2024 Apr 1
• The FDA in the Crosshairs-Science, Politics, and Abortion.
  Holly Fernandez Lynch, Aaron S Kesselheim> ;JAMA. 2024 Mar 25
• Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
  Massimiliano Russo, Luca Maini, Kimberly Feng, Aaron S Kesselheim, Benjamin N Rome> ;JAMA Health Forum. 2024 Mar 1
• Biologic patent challenges under the America Invents Act.
  Victor L Van de Wiele, S Sean Tu, Aaron S Kesselheim> ;Nature Biotechnology. 2024 Mar 1
• Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
  Ameet Sarpatwari, Sajeev Kohli, S Sean Tu, Aaron S Kesselheim> ;JAMA. 2024 Mar 19
• 1 citations
  Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.
  Egilman, A., Avorn, J., Raymakers, A., Kesselheim, A., Rome, B.> ;JAMA Dermatology. 2024 Feb 21
• How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.
  Sarpatwari, A., Lu, Z., Russo, M., Zakoul, H., Lee, S., Toyserkani, G., Zhou, E., LaCivita, C., Shaw, K., Zendel, L., Dal Pan, G., Kesselheim, A.> ;Clinical Pharmacology and Therapeutics. 2024 Feb 20
• Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.
  Tessema, F., Lalani, H., Kesselheim, A., Rome, B.> ;Journal of General Internal Medicine. 2024 Feb 6
• Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
  Adam J N Raymakers, Aaron S Kesselheim, Arash Mostaghimi, William B Feldman> ;JAMA Dermatology. 2024 Mar 1
• Association between changes in prices and out-of-pocket costs for brand-name clinician-administered drugs.
  Russo, M., Desai, R., Lalani, H., Kesselheim, A., Rome, B.> ;Health Services Research. 2024 Jan 21
• Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care.
  Hong, D., Avorn, J., Wyss, R., Kesselheim, A.> ;JAMA Network Open. 2024 Jan 2
• Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
  William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang> ;Annals of Internal Medicine. 2024 Jan 1
• Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey.
  Woloshin, S., Ji, R., Lu, Z., Darrow, J., Dhruva, S., Kesselheim, A., Redberg, R.> ;Health Affairs. 2024 Jan 1
• Administrative action on drug pricing: Lessons and opportunities for the Center for Medicare and Medicaid Innovation.
  Liu, I., Lalani, H., Kesselheim, A.> ;Journal of Managed Care & Specialty Pharmacy. 2024 Mar 1
• Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept.
  Helen Mooney, Matthew Martin, Liam Bendicksen, Aaron S Kesselheim, Benjamin N Rome, Hussain S Lalani> ;Journal of Managed Care & Specialty Pharmacy. 2024 Mar 1
• Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease.
  Alexander Chaitoff, Aaron S Kesselheim> ;Circulation. 2023 Dec 12
• Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis.
  John Kim, Aaron S Kesselheim, Riley Bove, Jerry Avorn, Benjamin N Rome> ;JAMA Neurology. 2024 Jan 1
• 1 citations
  Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
  Matthew Vogel, Olivia Zhao, William B Feldman, Amitabh Chandra, Aaron S Kesselheim, Benjamin N Rome> ;JAMA Internal Medicine. 2024 Jan 1
• Why Some Patients Overpay for Specialty Generic Drugs.
  Francis J Crosson, Aaron S Kesselheim> ;JAMA Internal Medicine. 2024 Jan 1
• Modernizing Federal Oversight of Laboratory-Developed Tests - Toward Safety, Validity, and Utility.
  Udit Singhal, Caroline Horrow, Aaron S Kesselheim, Todd M Morgan> ;The New England Journal of Medicine. 2023 Nov 9
• 2 citations
  Approval and therapeutic value of gene therapies in the US and Europe.
  Kerstin N Vokinger, Camille E G Glaus, Aaron S Kesselheim> ;Gene Therapy. 2023 Nov 1
• Outcomes of the 340B Drug Pricing Program: A Scoping Review.
  Ryan P Knox, Junyi Wang, William B Feldman, Aaron S Kesselheim, Ameet Sarpatwari> ;JAMA Health Forum. 2023 Nov 3
• Join now to see all

Journal Articles

• Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval  
  Aaron Kesselheim, MD, JAMA Internal Medicine
• Substitution of Generic Drugs and Biosimilars—Reply  
  Aaron Kesselheim, MD, JAMA Internal Medicine
• Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions  
  Aaron Kesselheim, MD, JAMA Internal Medicine
• Drug Prices, Rebates, and Discounts  
  William B Feldman, Aaron S Kesselheim, JAMA
• Missed Opportunities on Emergency Remdesivir Use  
  Aaron Kesselheim, MD, JAMA
• False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications  
  Steven Woloshin, Aaron S Kesselheim, The New England Journal of Medicine
• Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies  
  Mike Z Zhai, Carolyn T Lye, Aaron S Kesselheim, JAMA Internal Medicine
• Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act  
  Florence T Bourgeois, Aaron S Kesselheim, JAMA
• Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012  
  Aaron S Kesselheim, Michael S Sinha, JAMA
• Medicare Spending on Brand-Name Combination Medications vs Their Generic Constituents  
  Aaron Kesselheim, MD, JAMA
• Feature Patent Term Restoration for Top-Selling Drugs in the USA  
  Aaron Kesselheim, MD, ScienceDirect
• Join now to see all